Clinical Trial Update: A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating veliparib in combination with temozolomide in metastatic melanoma has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Temozolomide (Temozolomide)
• Veliparib (veliparib)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Melanoma, Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2017-03-03